Samaritan's Oral HIV Entry Inhibitor Noted as a Show "Out of the Gate" in the Race for Approval Business Wire
click here to return to Business Wire main menu
DonateNow





Samaritan's Oral HIV Entry Inhibitor Noted as a Show "Out of the Gate" in the Race for Approval

Business Wire - August 18, 2005

LAS VEGAS-- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it is listed in the leading BioCentury, The Bernstein Report on BioBusiness, in an article titled "NO entry," as being a contender in the race for approval as an oral HIV entry inhibitor. Samaritan was listed third after GlaxoSmithKline and Pfizer with at least seven oral entry inhibitors in the race. Fuzeon, approved in 2003, was the first entry inhibitor to reach the market, but the uptake of the injected drug has been slow because it doesn't fit with the dominant oral HIV regimens.

http://www.samaritanpharma.com/images/biocenturyaugust05.pdf

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "The way we look at it is that any one of us can win, place or show. It doesn't matter, we'll all win with sales if we get to the market because patients prefer oral medications. We remain entirely enthusiastic, believing in SP-01A's ability to save lives, and will do everything we can to win this race."

Samaritan Pharmaceuticals: "We LIV....to Save Lives."

Samaritan Pharmaceuticals is a drug development company driven to commercialize its pipeline of innovative drugs for AIDS, Alzheimer's, CNS, Cancer and Cardiovascular disease. Samaritan, in collaboration with Georgetown University, is advancing 8 promising compounds, out of its pipeline of 250 possible drug candidates. Samaritan's patent portfolio consists of 3 issued patents and 48 pending patent applications; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

CONTACT: Samaritan Pharmaceuticals, Inc.

Gene Boyle, 702-735-7001

GeneBoyle@SamaritanPharma.com

SOURCE: Samaritan Pharmaceuticals, Inc.


050818
BW050806

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .